Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Mark A Wainberg"'
Autor:
Bluma G. Brenner, Mark A. Wainberg, Thibault Mesplède, Nathan Osman, Maureen Oliveira, Said Hassounah
Publikováno v:
AIDS. 32:1773-1780
Objectives Dolutegravir (DTG) has achieved better long-term suppression of HIV-1 replication than other integrase strand transfer inhibitors (INSTIs), such as raltegravir (RAL) and elvitegravir (EVG). In in-vitro drug washout experiments, we previous
Autor:
Ruxandra I. Ibanescu, Bluma G. Brenner, Mark A. Wainberg, Thibault Mesplède, Maureen Oliveira, Hanh T. Pham
Publikováno v:
AIDS. 30:2267-2273
Objective Recommended treatments for newly diagnosed HIV-positive individuals now focus on the integrase strand transfer inhibitors, raltegravir (RAL), elvitegravir (EVG) and dolutegravir (DTG). In treatment-naive individuals, cases of RAL-based and
Autor:
Daniela Moisi, Bluma G. Brenner, Ruxandra-Ilinca Ibanescu, Thibault Mesplède, Mark A. Wainberg, Maureen Oliveira
Publikováno v:
AIDS. 29:2255-2260
Objective Although the integrase inhibitor dolutegravir (DTG) has demonstrated greater resilience than other antiretroviral drugs at withstanding the emergence of HIV-1 resistance mutations, such substitutions can develop, albeit rarely, in treatment
Autor:
Maureen Oliveira, Thibault Mesplède, Mark A. Wainberg, Bluma G. Brenner, Daniela Moisi, Ilinca Ibanescu, Frédéric Ohnona
Publikováno v:
AIDS. 29:659-665
OBJECTIVE In treatment-naive HIV-positive individuals, the integrase strand-transfer inhibitor dolutegravir (DTG) has not been associated with emergent drug-resistance mutations, neither against this drug nor against other antiretroviral drugs that w
Publikováno v:
AIDS. 28:813-819
Objective Among 1222 antiretroviral-naive patients who received dolutegravir (DTG) as part of first-line therapy, none has developed resistance against this compound after 48-96 weeks of follow-up. Moreover, only four occurrences of virological failu
Autor:
Alonso Heredia, Mohammed N. Amin, Steven G. Deeks, Maureen Oliveira, Robert R. Redfield, Charles B. Davis, Mark A. Wainberg, Lai-Xi Wang, Nhut Le
Publikováno v:
AIDS (London, England), vol 28, iss 3
Objective The M184V mutation in the HIV-1 reverse transcriptase gene is frequent (>50%) in patients, both in resource-rich and resource-limited countries, conferring high-level resistance (>100-fold) to the cytosine analog reverse transcriptase inhib
Autor:
Mark A. Wainberg, Bluma G. Brenner
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 63:S248-S254
The success of the HIV Prevention Trials Network 052 trial has led to revisions in HIV-1 treatment guidelines. Antiretroviral therapy may reduce the risk of HIV-1 transmissions at the population level. The design of successful treatment as prevention
Publikováno v:
Current Opinion in Infectious Diseases. 26:43-49
Purpose of review Integrase strand transfer inhibitors (INSTIs) have become a key component of antiretroviral therapy since the approval of twice-daily raltegravir in 2007 and the more recent approval of elvitegravir in 2012. At the same time, a thir
Publikováno v:
AIDS. 21:665-675
Objectives: To determine the underlying biochemical mechanisms responsible for the diminished viral replicative capacity associated with K65R/M184V-containing viruses. Methods: We studied the efficiency of (-)ssDNA synthesis by recombinant wild-type
Autor:
Dan Turner, Mark A. Wainberg, Daniela Moisi, Michel Roger, Bluma G. Brenner, Jean-Pierre Routy, Zeev Rosberger
Publikováno v:
JAIDS Journal of Acquired Immune Deficiency Syndromes. 37:1627-1631
This study compared the incidence of HIV-1 variants harboring mutations conferring resistance to thymidine analogues, ie, thymidine analogue mutations (TAMs), nonnucleoside reverse transcriptase (RT) inhibitors (NNMs), lamivudine (3TC) (ie, M184V), a